Foley & Lardner LLP Partner Kyle Faget was quoted in the MedTech Dive article, “3 key FDA topics for medtechs in 2022,” about the October 2021 release of the FDA’s list of proposed draft and final medical device guidance documents for fiscal year 2022, including the final guidance on clinical decision support (CDS) software.
Faget said that “The risk-based approach to enforcement that FDA issued previously is not easy for [technology] developers to follow. FDA needs to provide more clarity for developers as to where the boundaries are for each one of those categories.”
Faget is co-chair of Foley’s Health Care and Life Sciences Practice Groups.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”